Something went wrong with the connection!

Warm Autoimmune Hemolytic Anemia (WAIHA) Market, Size, Share, Trends, Epidemiology Forecast till 2030

 Breaking News
  • No posts were found

Warm Autoimmune Hemolytic Anemia (WAIHA) Market, Size, Share, Trends, Epidemiology Forecast till 2030

September 03
18:03 2020
Warm Autoimmune Hemolytic Anemia (WAIHA) Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia (WAIHA) Market Insights, Epidemiology and Market Forecast-2030′ report delivers an in-depth understanding of the disease,historical &forecasted epidemiology as well as the market trends of WAIHAs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Warm Antibody Hemolytic Anemia (WAIHA) is an autoimmune disorder characterized by the premature destruction of healthy red blood cells by autoantibodies. It is a common disorder directed against self RBCs.

 

Market Insight

Warm Autoimmune Hemolytic Anemia  market size in 7MM in 2017wasUSD 368 million  

Warm Autoimmune Hemolytic Anemia current market does not possess any approved therapy and relies only on the symptomatic treatment alternatives. The management of WAIHA has long been and still is mainly empirical or based on uncontrolled retrospective studies. The treatment landscape is primarily occupied by transfusion and supportive measures, corticosteroids, intravenous immunoglobulin (IVIG), danazol, rituximab, splenectomy, immunosuppressive drugs, and lastly hematopoietic stem cell transplantation (HSCT).

In a nutshell, it can be summarized that the traditional treatment options for WAIHA include corticosteroids, splenectomy, and conventional immunosuppressive drugs. Over the years, however, newer options have become available with considerable evidence of success.

They are used mainly in patients who fail to respond to splenectomy, those who relapse after splenectomy, and those who cannot maintain stable hemoglobin levels without unacceptably high doses of corticosteroids. Considering the high unmet medical need and the shortage of approved products, research is ongoing to develop other novel therapies. Although it is too soon to predict their market presence, it can be assumed that the landscape composition will undergo a significant transition in the near future.

The dynamics of the WAIHA market are anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies, i.e., Fostamitinib (Rigel Therapeutics), APL-2 (Apellis Pharmaceuticals), M281 (Momenta Pharmaceuticals), and few others during the forecast period 2020–2030. 

Warm Autoimmune Hemolytic Anemia Market Drivers

  • Increased market opportunity
  • Increasing awareness
  • Increase in number of research initiatives

Warm Autoimmune Hemolytic Anemia Market Barriers

  • Diagnostic delays in case of idiopathic WAIHA
  • Lack of approved therapies
  • Chances of relapse

Request for sample pages
Table of contents

1. Key Insights

2. Executive Summary

3. SWOT Analysis

4. wAIHA Market Overview at a Glance

4.1. Market Share (%) Distribution of wAIHA in 2017

4.2. Market Share (%) Distribution of wAIHA in 2030

5. Disease Background and Overview

5.1. Introduction

5.2. Types

5.3. Causes

5.4. Signs and Symptoms

5.5. Pathophysiology

5.6. Manifestations

5.7. Diagnosis

  • Immunohematological assessment of patients with AIHA
  • DAT-negative AIHA

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. KOL Views

6.3. 7MM Total Prevalent Patient Population of wAIHA

6.4. Assumptions and Rationale: 7MM

7. Country Wise-Epidemiology of wAIHA

7.1. The United States

7.1.1. Total Prevalent Cases of AIHA in the United States

7.1.2. Diagnosed Prevalence of wAIHA in the United States

7.1.3. Type-specific Prevalence of wAIHA in the United States

7.1.4. Gender-specific Prevalence of wAIHA in the United States

7.2. EU5

7.2.1. Germany

7.2.1.1. Total Prevalent Cases of AIHA in Germany

7.2.1.2. Diagnosed Prevalence of wAIHA in Germany

7.2.1.3. Type-specific Prevalence of wAIHA in Germany

7.2.1.4. Gender-specific Prevalence of wAIHA in Germany

7.2.2. France

7.2.2.1. Total Prevalent Cases of AIHA in France

7.2.2.2. Diagnosed Prevalence of wAIHA in France

7.2.2.3. Type-specific Prevalence of wAIHA in France

7.2.2.4. Gender-specific Prevalence of wAIHA in France

7.2.3. Italy

7.2.3.1. Total Prevalent Cases of AIHA in Italy

7.2.3.2. Diagnosed Prevalence of wAIHA in Italy

7.2.3.3. Type-specific Prevalence of wAIHA in Italy

7.2.3.4. Gender-specific Prevalence of wAIHA in Italy

7.2.4. Spain

7.2.4.1. Total Prevalent Cases of AIHA in Spain

7.2.4.2. Diagnosed Prevalence of wAIHA in Spain

7.2.4.3. Type-specific Prevalence of wAIHA in Spain

7.2.4.4. Gender-specific Prevalence of wAIHA in Spain

7.2.5. The United Kingdom

7.2.5.1. Total Prevalent Cases of AIHA in the UK

7.2.5.2. Diagnosed Prevalence of wAIHA in the UK

7.2.5.3. Type-specific Prevalence of wAIHA in the UK

7.2.5.4. Gender-specific Prevalence of wAIHA in the UK

7.3. Japan

7.3.1. Total Prevalent Cases of AIHA in Japan

7.3.2. Diagnosed Prevalence of wAIHA in Japan

7.3.3. Type-specific Prevalence of wAIHA in Japan

7.3.4. Gender-specific Prevalence of wAIHA in Japan

8. Treatment and Management of wAIHA

8.1. Sequential approach to treatment options for w-AIHA and common dosing regimens

8.1.1. First-line therapy

8.1.1.1. Corticosteroids

8.1.2. Second-line therapy

8.1.2.1. Splenectomy

8.1.2.2. Rituximab

8.1.2.3. Immunosuppressive drugs

8.1.2.4. Other Options

8.2. British Guidelines for WAIHA treatment

9. Case Study

10. Patient Journey

12. Unmet Needs

13. Emerging Therapies

13.1. Fostamatinib: Rigel Pharmaceuticals

13.1.1. Product Description

13.1.2. Other Development Activities

13.1.3. Clinical Development

13.1.3.1. Clinical Trials Information

13.1.4. Safety and Efficacy

13.2. APL-2: Apellis Pharmaceuticals, Inc.

13.2.1. Product Description

13.2.2. Other Development Activities

13.2.3. Clinical Development

13.2.3.1. Clinical Trials Information

13.2.4. Safety and Efficacy

13.3. M281: Momenta Pharmaceuticals

13.3.1. Product Description

13.3.2. Other Development Activities

13.3.3. Clinical Development

13.3.3.1. Clinical Trials Information

13.3.4. Safety and Efficacy

13.4. IMVT-1401: Immunovant

13.4.1. Product Description

13.4.2. Other Development Activities

13.4.3. Clinical Development

13.4.3.1. Clinical Trials Information

13.4.4. Safety and Efficacy

13.5. ALXN1830/SYNT001: Alexion Pharmaceuticals, Inc.

13.5.1. Product Description

13.5.2. Other Development Activities

13.5.3. Clinical Development

13.5.4. Clinical Trials Information

13.5.5. Product Profile

14. Other Promising Candidates

14.1. BIV009 (Sutimlimab): Sanofi

14.1.1. Product Description

14.1.2. Other Development Activities

14.1.3. Clinical Development

14.1.4. Clinical Trials Information

14.1.5. Safety and Efficacy

14.1.6. Product Profile

15. wAIHA: 7 Major Market Analysis

15.1. Key Findings

15.2. Market Size of wAIHA in 7MM

15.3. KOL Views

16. Market Outlook by Country

16.1. The United States: Market Outlook

16.2. United States Market Size

16.2.1. Total Market Size of wAIHA

16.2.2. Market Size of wAIHA by Therapies

17. EU-5 Countries: Market Outlook

17.1. Germany

17.1.1. Total Market size of wAIHA

17.1.2. Market Size of wAIHA by Therapies

17.2. France

17.2.1. Total Market Size of wAIHA

17.2.2. Market Size of wAIHA by Therapies

17.3. Italy

17.3.1. Total Market Size of wAIHA

17.3.2. Market Size of wAIHA by Emerging Therapies

17.4. Spain

17.4.1. Total Market Size of wAIHA

17.4.2. Market Size of wAIHA by Therapies

17.5. United Kingdom

17.5.1. Total Market Size of wAIHA

17.5.2. Market Size of wAIHA by Therapies

18. Japan: Market Outlook

18.1.1. Total Market Size of wAIHA

18.1.2. Market Size of wAIHA by Therapies

19. Market Drivers

20. Market Barriers

21. Appendix

21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Calendar

September 2020
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  

Categories